Avant Immunotherapeutics In-Play

Another stock that is doing well today is Avant Immunotherapeutics (AVAN, $18.75, up $4.74) which is up 33% after hitting a high of $19.79 earlier in the session. The company released data showing their cancer vaccine CDX-110 more than doubled the survival time in certain brain cancer patients.

The 23 patients the researchers tested with a type of brain tumor called glioblastoma multiforme lived an average 33 months longer. The Phase II data was also presented at the American Society of Clinical Oncology annual meeting. The doctor who presented the study said “that is almost unheard of” when talking about the survival rate.

This was certainly good news for Avant Immunotherapeutics but it’s also good news for Pfizer (PFE, $19.16, down $0.20) which will license the rights. Pfizer and Avant announced the deal last month as Pfizer will pay $40 million upfront plus a $10 equity investment in Avant.

Although Avant does not trade options and the stock’s big jump makes it even harder to justify getting in at current levels, Pfizer could be the better play if you are wanting a piece of the action. I mentioned Pfizer a month ago when the stock was at $19.91 and said back then how I though the stock was undervalued. Click here to read the entire review.

Not much has changed with Pfizer since except that the stock is lower and the dividend is up to 6.6%.

Rick Rouse
Rick@OptionsMentoring.com

]]>

Leave a reply Cancel reply

CFTC Disclosure:

GOVERNMENT REGULATIONS REQUIRE DISCLOSURE OF THE FACT THAT WHILE THESE METHODS MAY HAVE WORKED IN THE PAST, PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE PERFORMANCE. WHILE THERE IS A POTENTIAL FOR PROFITS THERE IS ALSO A RISK OF LOSS. A LOSS INCURRED IN CONNECTION WITH Momentum Options Trading, LLC CAN BE SIGNIFICANT. YOU SHOULD THEREFORE CAREFULLY CONSIDER WHETHER TRADING IS SUITABLE FOR YOU IN LIGHT OF YOUR FINANCIAL CIRCUMSTANCE. THERE IS SUBSTANTIAL RISK IN TRADING. A LOSS INCURRED IN CONNECTION WITH FUTURES TRADING CAN BE SIGNIFICANT. WE MAKE NO CLAIM REGARDING PAST OR FUTURE PERFORMANCE. WE MERELY TRACK EVERY TRADE AND SHOW THE PERFORMANCE OF ALL TRADES THE SYSTEM OR NEWSLETTER PRODUCES. SIMULATED TRADING IS DIFFERENT THAN TRADING REAL MONEY. HYPOTHETICAL RESULTS ARE NOT REAL RESULTS. PLEASE CONTACT YOUR BROKER ABOUT THE RISK OR TRADING STOCKS, OPTIONS OR FUTURES. ALL COMMUNICATIONS ARE OPINIONS NOT ADVICE.

CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

Blog